SCHEMBL5063104

SCHEMBL5063104

Cn1cc(-c2nccc(Oc3ccc(F)c(NC(=O)Nc4cc(C(C)(C)C)nn4-c4cccc(C#N)c4)c3)n2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.48
MAP3K7 O43318 2/20 0.48
SRC P12931 2/20 0.47
SYK P43405 2/20 0.47
MAPK12 P53778 2/20 0.47
BRAF P15056 15/20 0.47
KCNH2 Q12809 1/20 0.46
PLK4 O00444 1/20 0.43
ACOX3 O15254 1/20 0.43
DYRK3 O43781 1/20 0.43
JAK2 O60674 1/20 0.43
ERN1 O75460 1/20 0.43
RPS6KA4 O75676 1/20 0.43
STK10 O94804 1/20 0.43
MAP4K4 O95819 1/20 0.43
ABL1 P00519 1/20 0.43
RAF1 P04049 1/20 0.43
NTRK1 P04629 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2904909 0.90 SRC (0.41) MAPK14SRCSYKMAPK12BRAF
SCHEMBL5063859 0.89 MAPK14 (0.49) MAPK14MAP3K7SRCSYKMAPK12
SCHEMBL2924836 0.89 MAPK14 (0.48) MAPK14MAP3K7SRCSYKMAPK12
SCHEMBL3664166 0.86 MAPK14 (0.53) MAPK14BRAFABL1RAF1NTRK1
SCHEMBL5063866 0.85 MAPK14 (0.48) MAPK14MAP3K7SRCSYKBRAF
SCHEMBL5060337 0.84 MAPK14 (0.60) MAPK14MAP3K7SRCSYKBRAF
Hydrochloric Acid SCHEMBL5063078 0.83 MAPK14 (0.60) MAPK14MAP3K7SRCSYKBRAF
SCHEMBL3627787 0.80 MAPK14 (0.62) MAPK14BRAFABL1NTRK1RET
SCHEMBL2925649 0.80 MAP3K7 (0.52) MAPK14MAP3K7SRCSYKMAPK12
SCHEMBL5062102 0.80 MAP3K7 (0.61) MAPK14MAP3K7SRCMAPK12BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481736-A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases Deciphera Pharmaceuticals, LLC. (US) 2012-08-01 EP disclosed
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES BRAF, RET, KIT MAPK14 281/4885MAP3K7 59/4885SRC 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.